Novo Nordisk Partners with AWS to Accelerate Drug Development Using AI

Novo Nordisk and Amazon Web Services (AWS) announced a strategic partnership on August 14, 2026, aimed at accelerating the drug discovery process through Agentic AI and cloud technology, modernizing Novo Nordisk's operational system. The core of this collaboration is the newly established AI Joint Innovation Center in London, which brings together AWS engineers, AI experts, and application scientists to work closely with Novo Nordisk's R&D team to enhance research efficiency and shorten the time to market for innovative drugs.

Details of the Collaboration

According to the agreement, AWS will become Novo Nordisk's preferred cloud service provider and strategic AI partner. The two parties will combine AWS's AI technology with Novo Nordisk's data and insights to jointly enhance drug development efficiency, particularly in the research cycle from drug target discovery to initiating the first human trial dose.

Executive Perspectives

Mike Doustdar, Global President and CEO of Novo Nordisk, stated, "Partnering with AWS aims to make AI a key engine driving Novo Nordisk's innovative development. By combining our research expertise with the tools and services AWS has tailored for the life sciences industry, we are accelerating the drug discovery process and developing responsible AI solutions that bring tangible progress to patients with serious chronic diseases."

Additionally, AWS CEO Matt Garman expressed his anticipation for the collaboration, noting, "Everything we do in partnership with Novo Nordisk revolves around a common goal: to bring the right drugs to patients faster."

Future Outlook

This collaboration is not only based on the long-term relationship between the two parties but will also build a secure and reliable technological foundation to accelerate the transformation of innovative ideas into new therapies that benefit patients worldwide. Novo Nordisk plans to utilize AWS services such as Amazon Bio Discovery and Amazon Bedrock to identify drug targets, accelerate new therapy design, and integrate genomics, imaging, and clinical data to better apply breakthroughs in early research to clinical trial design.

Furthermore, Novo Nordisk will leverage Amazon Bedrock AgentCore to enhance overall operational efficiency through AI Agents, further strengthening its research capabilities in the field of chronic diseases.